Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Gains from Sales and Divestitures (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Gains from Sales and Divestitures data on record, last reported at $2.3 million in Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 0.69% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $2.3 million, up 0.69%, while the annual FY2025 figure was $2.3 million, 0.69% up from the prior year.
  • Gains from Sales and Divestitures reached $2.3 million in Q4 2025 per TGTX's latest filing, up from $1.8 million in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $6.3 million in Q4 2022 and bottomed at $682840.0 in Q1 2021.
  • Average Gains from Sales and Divestitures over 5 years is $2.0 million, with a median of $1.8 million recorded in 2025.
  • Peak YoY movement for Gains from Sales and Divestitures: surged 382.98% in 2022, then tumbled 60.26% in 2023.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $1.3 million in 2021, then soared by 382.98% to $6.3 million in 2022, then crashed by 60.26% to $2.5 million in 2023, then decreased by 9.91% to $2.3 million in 2024, then rose by 0.69% to $2.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $2.3 million in Q4 2025, $1.8 million in Q3 2025, and $1.6 million in Q2 2025.